fbpx

molecules of the month

saridegib

oral SMO inhibitor

Ph. III for Gorlin syndrome

from SAR of in-house library hit

Press release, January 27, 2023

Infinity Pharmaceuticals, Cambridge, MA (Sol-Gel)

oral SMO & Hh pathway inhibitor Ph. III for Gorlin syndrome from SAR of in-house library hit semisynthesis of cyclopamine-derived HH pathway antagonists Press release, January 27, 2023 Infinity Pharmaceuticals, Cambridge, MA (Sol-Gel)
4 mins read

What is it? Saridegib (IPI-926, patidegib) is a Smoothened receptor (SMO) antagonist and hedgehog pathway inhibitor currently in Ph. III trials for Gorlin syndrome. The molecule is a semisynthetic analog of the naturally-occuring SMO antagonist, cyclopamine, and has a long history and originates from Infinity Pharmaceuticals. After a clinical disappointment as an oral therapy for myelofibrosis and chondrosarcoma in 2012, Infinity out-licensed the molecule to PellePharm in 2013, a company later backed by BridgeBio. Recently, it again changed hands from BridgeBio/PellePharm to Sol-Gel Technologies in a ~$75M transaction. Sol-Gel plans to continue development of the molecule for Gorlin syndrome and basal cell carcinomas as a topical treatment to avoid systemic toxicities, giving this older molecule hope of a new life.…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: